Cargando…

Immunogenicity of Sarilumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant to Disease-Modifying Antirheumatic Drugs

INTRODUCTION: This open-label study evaluated the immunogenicity, safety, and efficacy of sarilumab monotherapy in patients with active, moderate-to-severe rheumatoid arthritis (RA) and inadequate response or intolerance to prior conventional synthetic disease-modifying antirheumatic drugs. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Wells, Alvin F., Parrino, Janie, Mangan, Erin K., Paccaly, Anne, Lin, Yong, Xu, Christine, Fan, Chunpeng, Graham, Neil M. H., van Hoogstraten, Hubert, Torri, Albert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6702535/
https://www.ncbi.nlm.nih.gov/pubmed/31090044
http://dx.doi.org/10.1007/s40744-019-0157-3